TY - JOUR
T1 - Amyloid β protein in plasma from patients with sporadic Alzheimer' s disease
AU - Tamaoka, Akira
AU - Fukushima, Tetsuo
AU - Sawamura, Naoya
AU - Ishikawa, Kin'ya
AU - Oguni, Eiichi
AU - Komatsuzaki, Yasuko
AU - Shoji, Shin'ichi
N1 - Funding Information:
This work was in part supported by a grant from the University of Tsukuba project research,b y a Grant-in-Aid of the Japan Medical Association, by a Grant-in-aid of ON0 Medical Research Foundation, by a Grant-in-Aid of Sandoz Foundation for Gerontological Research and by Grants-in-Aid for Scientific Researchf rom the Ministry of Education, Science and Culture, Japan to A.T. The authors thank Asano Asami, MS, and Nobuhiro Suzuki, PhD (Discovery Research Division, Takeda Chemical Industries, Ltd., Tsukuba, Ibaraki, Japan) for helpful discussions.
PY - 1996/9/15
Y1 - 1996/9/15
N2 - Fibrillar amyloid β protein (Aβ) deposition is increased in the brains of patients with Alzheimer's disease (AD), and is manifested as senile plaques (SPs) and congophilic angiopathy (CA). Aβ40 and Aβ42(43), two chief species of Aβ, are documented in SPs and CA, as well as in cerebrospinal fluid (CSF) and cell culture media. Aβ42(43) is the major component of diffuse plaques, the earliest form of SPs. Thus, we hypothesized that determination of the amount of Aβ42(43) in CSF or plasma might provide a diagnostic laboratory test for AD. We measured amounts of different Aβ species in plasma from 28 patients with sporadic probable AD, 40 age-matched neurologic patients without dementia and 25 age-matched normal controls using enzyme-linked immunosorbent assays (ELISAs). Plasma concentrations of Aβ1-40 and Aβ1-42(43) did not significantly differ among these groups. These findings suggest the unlikelihood that plasma Aβ assays would be useful as a diagnostic tool for AD.
AB - Fibrillar amyloid β protein (Aβ) deposition is increased in the brains of patients with Alzheimer's disease (AD), and is manifested as senile plaques (SPs) and congophilic angiopathy (CA). Aβ40 and Aβ42(43), two chief species of Aβ, are documented in SPs and CA, as well as in cerebrospinal fluid (CSF) and cell culture media. Aβ42(43) is the major component of diffuse plaques, the earliest form of SPs. Thus, we hypothesized that determination of the amount of Aβ42(43) in CSF or plasma might provide a diagnostic laboratory test for AD. We measured amounts of different Aβ species in plasma from 28 patients with sporadic probable AD, 40 age-matched neurologic patients without dementia and 25 age-matched normal controls using enzyme-linked immunosorbent assays (ELISAs). Plasma concentrations of Aβ1-40 and Aβ1-42(43) did not significantly differ among these groups. These findings suggest the unlikelihood that plasma Aβ assays would be useful as a diagnostic tool for AD.
KW - Alzheimer's disease
KW - Amyloid angiopathy
KW - Amyloid β protein
KW - Enzyme-linked immunosorbent assay
KW - Plasma
KW - Senile plaque
UR - http://www.scopus.com/inward/record.url?scp=0030587520&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030587520&partnerID=8YFLogxK
U2 - 10.1016/0022-510X(96)00143-8
DO - 10.1016/0022-510X(96)00143-8
M3 - Article
C2 - 8880695
AN - SCOPUS:0030587520
VL - 141
SP - 65
EP - 68
JO - Journal of the Neurological Sciences
JF - Journal of the Neurological Sciences
SN - 0022-510X
IS - 1-2
ER -